G. Krishna et al., Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2, INT J PHARM, 222(1), 2001, pp. 77-89
Highly lipophilic compounds are often encountered in the early stages of dr
ug discovery. The apparent permeability (Papp) of these compounds in Caco-2
cell could be underestimated because of considerable retention by the Caco
-2 monolayer and non-specific binding to transwell surface. We have utilize
d a general approach for the determination of permeability of these compoun
ds, which includes the addition of 1-5% DMSO in the apical (AP) and 4% bovi
ne serum albumin (BSA) in the basolateral (BA) side. Two highly lipophilic
and highly protein bound Schering compounds, SCH-A and SCH-B, exhibited poo
l recovery and low Papp in the conventional Caco-2 system that included 1%
DMSO in the AP and BA sides. In contrast, both compounds were well absorbed
in cynomolgus monkeys. Inclusion of BSA (up to 4%) in the BA side provided
necessary absorptive driving force similar to in vivo sink conditions impr
oving both recovery and Papp of these compounds as well as progesterone, a
model highly lipophilic and highly protein bound compound. Whereas, the rec
overy and Papp of mannitol thigh recovery, low permeability) and propranolo
l thigh recovery, high permeability) remained unaffected. The presence of 4
% BSA increased Papp of SCH-A, SCH-B, and progesterone by five-, four-, and
three-fold, respectively. We also compared this approach with a second, ba
sed on the disappearance of the compound from the AP side, which resulted i
n a reasonable estimate of the permeability (23.3 x 10(-6) cm/s) for SCH-A.
The results demonstrated that the reliable estimates of permeability of hi
ghly lipophilic compounds that are subjected to considerable retention by t
he cell monolayer and exhibit non-specific binding are obtained by the addi
tion of BSA to the BA side. (C) 2001 Published by Elsevier Science B.V.